glp 1 retatrutide 8 weeks BREAKING NEWS! Phase 3 data on just dropped. 28% average weight loss at 80 weeks. 30% at 104 weeks. The next generation of obesity medications is almost here. #obesitymedicine #womenshealth #obesitydoctor Survey shows GLP-1 weight-loss Weekly Injection Color:Pink

glp 1 retatrutide 8 weeks BREAKING NEWS! Phase 3 data on just dropped. 28% average weight loss at 80 weeks. 30% at 104 weeks. The next generation of obesity medications is almost here. #obesitymedicine #womenshealth #obesitydoctor Survey shows GLP-1 weight-loss Weekly Injection Color:Pink

Survey shows GLP-1 weight-loss drugs are changing sex and dating for 50–60% of users: Kinsey Institute : Indiana University

[DOI] [PubMed] [Google Scholar] Kuna RS, Girada SB, Asalla S, Vallentyne J, Maddika S, Patterson JT, Smiley DL, DiMarchi RD, Mitra P

Weekly Injection

Color:Pink

View image online ( Patient holding injectable Use of GLP-1 receptor agonists—with or without glucose-dependent insulinotropic polypeptide (GIP)—may be associated with improved clinical outcomes in patients with Type 1 diabetes, according to a large retrospective analysis published in Diabetes Technology & Therapeutics